Incannex Healthcare Inc. - 8-K Filing
Incannex Healthcare commenced patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, received a U.S. patent covering its lead compound with baseline expiry to 2040, and reported $70 million cash on hand as of August 31, 2026. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $IXHL